Skip to content

Study · Animal study (in vivo) · mouse · 2022

6 results

Elamipretide treatment during pregnancy ameliorates the progression of polycystic kidney disease in maternal and neonatal mice with PKD1 mutations.

Daneshgar N, Liang PI, Lan RS, Horstmann MM, Pack L, Bhardwaj G, Penniman CM, O'Neill BT, Dai DF

Kidney international22 Dec 2021Cited by 11 (Europe PMC)

PMID34953771 (opens in a new tab)PMCIDPMC9038630 (opens in a new tab)DOI10.1016/j.kint.2021.12.006 (opens in a new tab)PepBankPUB-34953771
Source linkPubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In pregnant Pkd1 RC/RC mice, elamipretide ameliorated the progression of kidney disease.

    In plain wordsIn pregnant mice with polycystic kidney disease, elamipretide slowed the progression of kidney disease.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseKidney disease progression in pregnant mice
    Study

    mousen: not reported in source

    Pkd1 RC/RC mice with polycystic kidney disease
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Elamipretide was found to ameliorate the progression of kidney disease in pregnant Pkd1RC/RC mice, in parallel with attenuation of ERK1/2 phosphorylation and improvement of mitochondrial supercomplex formation.
    1 context sentence
    Summary · context
    Since pregnancy itself may increase the risk for ADPKD progression, we investigated the safety and efficacy of Elamipretide, a mitochondrial-protective tetrapeptide.
  2. 02AnimalAnimal study (in vivo)Mechanism

    In pregnant Pkd1 RC/RC mice, elamipretide attenuated ERK1/2 phosphorylation.

    In plain wordsIn pregnant mice with polycystic kidney disease, elamipretide lowered ERK1/2 signalling.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseERK1/2 phosphorylation
    Study

    mousen: not reported in source

    Pkd1 RC/RC mice with polycystic kidney disease
    Outcome group
    Receptor activity and mechanism · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Elamipretide was found to ameliorate the progression of kidney disease in pregnant Pkd1RC/RC mice, in parallel with attenuation of ERK1/2 phosphorylation and improvement of mitochondrial supercomplex formation.
    1 context sentence
    Summary · context
    Since pregnancy itself may increase the risk for ADPKD progression, we investigated the safety and efficacy of Elamipretide, a mitochondrial-protective tetrapeptide.
  3. 03AnimalAnimal study (in vivo)Mechanism

    In pregnant Pkd1 RC/RC mice, elamipretide improved mitochondrial supercomplex formation.

    In plain wordsIn pregnant mice with polycystic kidney disease, elamipretide improved how mitochondrial protein complexes form.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseMitochondrial supercomplex formation
    Study

    mousen: not reported in source

    Pkd1 RC/RC mice with polycystic kidney disease
    Outcome group
    Mitochondrial function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Elamipretide was found to ameliorate the progression of kidney disease in pregnant Pkd1RC/RC mice, in parallel with attenuation of ERK1/2 phosphorylation and improvement of mitochondrial supercomplex formation.
    1 context sentence
    Summary · context
    Since pregnancy itself may increase the risk for ADPKD progression, we investigated the safety and efficacy of Elamipretide, a mitochondrial-protective tetrapeptide.
  4. 04AnimalAnimal study (in vivo)Pharmacokinetics

    In mice, elamipretide passed through the placenta and breast milk.

    In plain wordsIn mice, elamipretide passed from mother to offspring through the placenta and breast milk.

    Peptide
    Elamipretide (SS-31)
    Outcome
    Not applicableTransfer through the placenta and breast milk
    Study

    mousen: not reported in source

    Pkd1 RC/RC mice with polycystic kidney disease
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Furthermore, Elamipretide was found to pass through the placenta and breast milk
    1 context sentence
    Summary · context
    Since pregnancy itself may increase the risk for ADPKD progression, we investigated the safety and efficacy of Elamipretide, a mitochondrial-protective tetrapeptide.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In neonatal Pkd1 RC/RC mice, elamipretide ameliorated aggressive infantile polycystic kidney disease.

    In plain wordsIn young mice with aggressive polycystic kidney disease, elamipretide improved the disease.

    Peptide
    Elamipretide (SS-31)
    Outcome
    DecreaseInfantile polycystic kidney disease
    Study

    mousen: not reported in source

    Pkd1 RC/RC mice with polycystic kidney disease
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated

    Source sentences

    Summary
    ameliorate aggressive infantile polycystic kidney disease without any observed teratogenic or harmful effect.
    1 context sentence
    Summary · context
    Since pregnancy itself may increase the risk for ADPKD progression, we investigated the safety and efficacy of Elamipretide, a mitochondrial-protective tetrapeptide.
  6. 06AnimalAnimal study (in vivo)Safety outcome

    In mice, no teratogenic or harmful effect of elamipretide was observed.

    In plain wordsIn mice, no birth defects or other harm from elamipretide were seen.

    Peptide
    Elamipretide (SS-31)
    Outcome
    No significant changeTeratogenic or harmful effects
    Study

    mousen: not reported in source

    Pkd1 RC/RC mice with polycystic kidney disease
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    without any observed teratogenic or harmful effect.
    1 context sentence
    Summary · context
    Since pregnancy itself may increase the risk for ADPKD progression, we investigated the safety and efficacy of Elamipretide, a mitochondrial-protective tetrapeptide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.